Column Group’s Oric Pharmaceuticals ORIC Stock Holding History

Column Group’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38.3M	Hold	3,540,777	–	–	43.53%	2
2026 Q1	$44.9M	Hold	3,540,777	–	–	44.55%	2
2025 Q4	$29M	Hold	3,540,777	–	–	34.98%	2
2025 Q3	$42.5M	Hold	3,540,777	–	–	52.48%	1
2025 Q2	$35.9M	Hold	3,540,777	–	–	54.68%	1
2025 Q1	$19.8M	Hold	3,540,777	–	–	44.67%	1
2024 Q4	$28.6M	Hold	3,540,777	–	–	51.26%	1
2024 Q3	$36.3M	Hold	3,540,777	–	–	52.16%	1
2024 Q2	$25M	Hold	3,540,777	–	–	35.12%	2
2024 Q1	$48.7M	Sell	3,540,777 -27,404	-0.8%	-$325K	30.33%	2
2023 Q4	$32.8M	Hold	3,568,181	–	–	21.69%	2
2023 Q3	$21.6M	Hold	3,568,181	–	–	14.33%	4
2023 Q2	$27.7M	Hold	3,568,181	–	–	10.75%	5
2023 Q1	$20.3M	Hold	3,568,181	–	–	7.35%	5
2022 Q4	$21M	Hold	3,568,181	–	–	7%	4
2022 Q3	$11.4M	Hold	3,568,181	–	–	2.53%	6
2022 Q2	$16M	Hold	3,568,181	–	–	3.4%	6
2022 Q1	$19.1M	Hold	3,568,181	–	–	3.53%	6
2021 Q4	$52.5M	Sell	3,568,181 -1,200,000	-25%	-$18.7M	7.13%	5
2021 Q3	$99.7M	Hold	4,768,181	–	–	11.34%	3
2021 Q2	$84.3M	Hold	4,768,181	–	–	11.94%	5
2021 Q1	$117M	Hold	4,768,181	–	–	11.19%	4
2020 Q4	$161M	Buy	+4,768,181	New	+$137M	14.64%	3

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AIHC Capital Management Central $104M AUM

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Column Group's ORIC Position: Q2 2026 in Review

Column Group held its Oric Pharmaceuticals (ORIC) position steady in Q2 2026 at 3,540,777 shares worth $38.3M. The position accounts for 43.53% of the portfolio, ranked #2.

Column Group first reported a position in ORIC in Q4 2020 and has held it in 23 quarters since. The position peaked at $161M in Q4 2020. 163 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

Column Group held 3,540,777 shares of Oric Pharmaceuticals worth $38.3M as of Q2 2026.
Column Group left its Oric Pharmaceuticals share count unchanged in Q2 2026.
Oric Pharmaceuticals made up 43.53% of Column Group's portfolio in Q2 2026, its #2 holding.
Column Group first reported a position in Oric Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
Column Group's Oric Pharmaceuticals position peaked at $161M in Q4 2020.
163 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Column Group's 13F filing for Q2 2026, filed 14 Aug 2026.